Skip to main content

Table 1 Clinical characteristics of patients with COVID-19

From: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients

  Total
N (%)
With ARDS
N (%)
Without ARDS
N (%)
p-value
Number of patients 53 28 25  
Age: years (Median + IQR) 63 (54–73) 61.5 (56–68) 66 (51–77) .417
Female sex 21 (39.6) 10 (35.7) 11 (44) .584
Evidence of COVID-19
 PCR (respiratory samples) 53 (100) 28 (100) 25 (100)  
 Chest radiograph / chest computed tomography 53 (100) 28 (100) 25 (100)  
Comorbidities
 Arterial hypertension 36 (67.9) 19 (67.9) 17 (68) .612
 Diabetes mellitus 15 (28.3) 5 (17.9) 10 (40) .160
 Dyslipidaemia 11 (20.8) 6 (21.4) 5 (20) .585
 Smoking 5 (9.4) 3 (10.7) 2 (8) .414
 Ex-smoking 1 (1.9) 1 (3.6) 0
 History of stroke/TIA 4 (7.5) 2 (7.1) 2 (8) .509
 History of traumatic brain injury 3 (6.7) 2 (7.1) 1 (4) .543
 Depression 7 (13.2) 5 (17.9) 2 (8) .426
 Coronary heart desease 12 (22.6) 8 (28.6) 4 (16) .076
 Atrial fibrillation 11 (20.8) 7 (25) 4 (16) .509
 History of myocardial infarction 8 (15.1) 8 (28.6) 0 .004
 Carotid artery stenosis 2 (3.8) 1 (3.6) 1 (4) .726
 History of cardiovascular surgery (stent/bypass) 4 (7.5) 3 (10.7) 1 (4) .533
Medication
 Antihypertensive drug 36 (67.9) 16 (57.1) 20 (80) .562
 Anticoagulant 21 (39.6) 18 (64.3) 3 (12) .0001
 Antidepressant 3 (6.7) 3 (10.7) 0 .335
 Anticonvulsant 2 (3.8) 0 2 (8) .466
 Anti-psychotic 5 (9.4) 5 (17.9) 0 .101
 Anti-parkinson 2 (3.8) 1 (3.6) 1 (4) .934
 Statins 6 (11.3) 2 (7.1) 4 (16) .309
 Immunosuppressant 8 (15.1) 5 (17.9) 3 (12) .513
 Other (Ibuprofen, Tilidine, L-Thyroxine, Pantoprazole, Salbutamol) 16 (30.2) 11 (39.3) 5 (20) .126
  1. ARDS Acute respiratory distress syndrome